• MOLOGEN to receive a EUR 3 million initial payment as well as a EUR 2 million equity investment • Milestone payments of above EUR 100 million and double digit royalties on net sales • Strong support for global development program of lefitolimod,...

Research License Agreement on Unique Technology to Assess Drug Effects on the Immune System in Vitro.

A study conducted by the 3.works institute from Düsseldorf confirms, that KNAUER is one of the companies in Germany with the best employer ratings. The results of the study will be published in cooperation with the renowned ZEIT publishing group.

Twenty-five years ago, an unusual inherited form of high blood pressure was first described in an Australian family. Its genetic cause, however, had remained elusive. Using modern sequencing methods, an international research team led by BIH Johanna...

Startupbootcamp Digital Health Berlin is now entering its 3rd cycle, and is one of the most serious health accelerators in the continent. How, you ask?

Regulation of adipose tissue metabolism as a potential treatment for heart failure

TissUse continues their successful collaboration with AstraZeneca to establish relevant Microphysiological System (MPS) models based on TissUse’s Multi-Organ-Chip technology.

Attention young scientists! 
Are you able to present your life science discovery in 3 minutes in a layman´s language? 
Then apply until April 25, win a pitch coaching and save your prize money at our Speed Lecture Award final @ BIONNALE on June 20 in...

Aesculap AG, a subsidiary of B. Braun Melsungen AG, together with Christoph Miethke announced the formation of the joint venture B. Braun Miethke GmbH & Co. KG.